Previous 10 | Next 10 |
-- Preparations continue for U.S. commercial launch in June 2022 in BBS and Alström syndrome, pending FDA approval -- -- First commercial sales of IMCIVREE in Germany and France expected in 2Q2022 – -- Enrollment completed in Phase 2 trial evaluating setm...
Rhythm Pharmaceuticals (NASDAQ:RYTM) is scheduled to announce Q4 earnings results on Tuesday, March 1st, before market open. The consensus EPS Estimate is -$0.93 and the consensus Revenue Estimate is $1.7M For further details see: Rhythm Pharmaceuticals Q4 2021 Earnings Preview
NEW YORK, NY / ACCESSWIRE / February 25, 2022 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Rhythm Pharmaceuticals, Inc. ("Rhythm" or the "Company") (NASDAQ:RYTM). Investors who purchased Rhythm securities are encouraged to obtain add...
Gainers: Lantheus (NASDAQ:LNTH) +34%. Evolent Health (NYSE:EVH) +18%. Clover Health (NASDAQ:CLOV) +10%. Liquidia (NASDAQ:LQDA) +10%. iRhythm Technologies (NASDAQ:IRTC) +8%. Losers: Orphazyme (NASDAQ:ORPH) -36%. Rhythm Pharmaceuticals (NASDAQ:RYTM) -24%. Tabu...
Rhythm Pharmaceuticals (NASDAQ:RYTM) is trading ~8% lower in the pre-market Thursday after the commercial-stage biopharma company announced that the U.S. Food and Drug Administration (FDA) had extended its supplemental New Drug Application (sNDA) for Imcivree. The company has sought...
-- FDA sets updated PDUFA goal date of June 16, 2022 -- -- Company also announces withdrawal of proposed Alström syndrome indication from Type II variation application under review by the EMA -- BOSTON, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (N...
BOSTON, Feb. 23, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced the promotions of Joe Shulman to Chief Technical Off...
BOSTON, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic diseases of obesity, today announced that it will host a live conference call and webcast...
Rhythm Pharmaceuticals (RYTM +12.1%) has recorded the biggest intraday gain since November 2020 after Ladenburg Thalmann upgraded the commercial-stage biopharmaceutical company to Buy from Neutral. The firm highlighted the prospects of Imcivree, an FDA-approved therapy marketed by the company...
Gainers: Aridis Pharmaceuticals ARDS +12%. Rhythm Pharmaceuticals RYTM +12%. Outset Medical (NASDAQ:OM) +10%. Masimo (NASDAQ:MASI) +8%. Vivos Therapeutics (NASDAQ:VVOS) +7%. Losers: 10x Genomics (NASDAQ:TXG) -16%. iSpecimen ISPC -10%. Poseida ...
News, Short Squeeze, Breakout and More Instantly...
Rhythm Pharmaceuticals Inc. Company Name:
RYTM Stock Symbol:
NASDAQ Market:
Rhythm Pharmaceuticals Inc. Website:
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today announced the appointment of Alastair “Al...
- European Commission decision anticipated in the second half of 2024 - BOSTON, June 28, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rar...
2024-06-14 11:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...